Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
krasg12 save search
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.24%
H: 0.08%
C: -2.42%
mk-1084 keytruda lung merck cancer cell treatment trial
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
ZNTL | $11.76 -6.44% -6.89% 850K
|
Health Technology
|
| O: -6.85%
H: 7.84%
C: 7.35%
pharmaceuticals preclinical meeting
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
Published: 2024-01-18 (Crawled : 23:00) - biospace.com/
VSTM | $9.29 -3.33% -3.44% 79K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.48%
lung avutometinib granted cancer cell treatment designation
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10 (Crawled : 13:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12 lung cancer cell treatment advanced
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
Published: 2024-01-03 (Crawled : 12:30) - bridgebio.com
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: -2.35%
H: 1.22%
C: -4.18%
bbo-8520 fda direct clearance application
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
Published: 2023-12-01 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.15%
H: 0.35%
C: -0.74%
ibi351 lung congress update cancer asia
China's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
Published: 2023-11-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.69%
H: 1.66%
C: 1.66%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.34%
H: 0.37%
C: 0.3%
ibi351 drug granted review designation medical application china
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
CCXI | News | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
lumakras cancer plus
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
Published: 2023-09-10 (Crawled : 16:20) - prnewswire.com
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
| Email alert
Add to watchlist
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
| Email alert
Add to watchlist
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
CCXI | News | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
lumakras plus
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
Published: 2023-08-21 (Crawled : 20:00) - prnewswire.com
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: -0.27%
H: 0.99%
C: -0.67%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.18%
H: 0.06%
C: -1.01%
lumakras fda treatment meeting application
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
Published: 2023-07-21 (Crawled : 12:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -14.97%
H: 11.97%
C: 8.9%
lung review update cancer cell treatment therapeutics
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
Published: 2023-06-20 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -1.15%
H: 0.16%
C: -1.94%
krasg12 treatment system results
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.8%
H: 0.23%
C: -1.06%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
ibi351 asco cancer meeting
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
Published: 2023-06-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.79%
H: 1.08%
C: 0.54%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.02%
H: 1.79%
C: 1.69%
ibi351 erbitux merck germany collaboration trial china therapy
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Published: 2023-05-30 (Crawled : 20:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.43%
H: 2.55%
C: -0.27%
krasg12 asco tumors treatment meeting potential
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
Published: 2023-05-15 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.22%
H: 0.14%
C: -0.2%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.34%
H: 1.13%
C: 1.07%
ibi351 designation
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
Published: 2023-04-26 (Crawled : 21:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.44%
H: 0.66%
C: -0.21%
krasg12 rapid tumors treatment communication
Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023
Published: 2023-04-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: -0.71%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.17%
H: 0.34%
C: -0.83%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.16%
H: 0.13%
C: -1.44%
ibi351 tumors meeting trial
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
Published: 2023-01-19 (Crawled : 23:00) - prnewswire.com
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.98%
H: 5.53%
C: 5.21%
krasg12 fda clearance enabling phase 1
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.